Invitation to offer for NHS Framework Agreement for Branded Pharmaceuticals for London – Tranche A (inc. Hepatitis C)
The value below is a framework or dynamic market ceiling: the maximum
that could be spent across all call-offs, not the value of a single contract.
Aggregate figures on this site exclude these to avoid double counting.
key details
| Value | £201,544,684 |
|---|---|
| Status | complete |
| Category (CPV) | 33600000 |
| Region | London |
| Deadline | 12 May 2016 |
| Contract start | 1 Sept 2016 |
| Contract end | 31 Aug 2018 |
| Procedure | open |
| SME suitable | Yes |
| OCID | ocds-b5fd17-8aa1c90f-adc9-11e6-9901-0019b9f3037b |
Award
| Supplier | Value | Date | Status |
|---|---|---|---|
| Multiple suppliers awarded | £197,864,546 | 24 Jul 2016 | active |
description
Invitation to offer for NHS Framework Agreement for Branded Pharmaceuticals for London – Tranche A (inc. Hepatitis C Medicines)
Offer reference number: CM/PHR/13/5426
Period of framework agreement: 1st September 2016 to 31st August 2018 plus an option to extend for up to 24 months
Hepatitis C Medicines - Period of framework agreement: 1st September 2016 to 31st August 2017 with an option to extend for up to 12 months
notice history
1 notice published against this procurement.
| Published | Type | Regime | Notice |
|---|---|---|---|
| 18 Nov 2016 | Award (award) | · | fe77aee3-e30f-46ee-bfd4-ee52bb109132-93496 |
more from COMMERCIAL MEDICINES UNIT
- NHS National Framework Agreement for the supply of Nitric Oxide Therapy. To include the supply of gas, rental of cylinders and delivery equipment, maintenance and consumables · £22,000,000 · 17 Aug 2018
- NHS National Framework Agreement for the supply of Recombinant Factor IX products for the treatment of bleeding disorders · £50,600,000 · 17 Aug 2018
- NHS National Framework Agreement for the supply of Human Cell Line Recombinant Factor VIII products · £4,125,000 · 17 Aug 2018
- NHS Framework Agreement for Branded Pharmaceuticals - North of England Tranche A. · £575,675,600 · 24 Apr 2017
- NHS Framework Agreement for the Midlands and East Pharmacy Purchasing Group for the supply of Proprietary Pharmaceuticals - Tranche B · £102,379,487 · 24 Apr 2017
- National Framework Agreement for the Supply of Immunoglobulin · £647,709,424 · 27 Mar 2017
- Contract for the supply of BCG vaccine · 9 Jan 2017
- Invitation to offer for NHS National Framework Agreement for the supply of Human Albumin and Human Anti-D Immunoglobulin · £19,539,253 · 23 Dec 2016
all contracts from this buyer →
similar contracts awarded
Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.
- Radiopharmaceutical Products - Poltech · The Christie NHS Foundation Trust · £39,000
- NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026 · NHS England · £592,363,416
- NHS National Generics Pharmaceuticals - Supply Chain Resilience · NHS England · £52,447,296
- Generic, Branded Generic & Proprietary Medicinal Products - Group 18 · Regional Business Services Organisation, Procurement and Logistics Service · £1,800,000,000
- Generic Drugs – Injections/Infusions 2 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £6,535,850
- Transitional Drugs 7 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £53,566,932
- NP90726m Vedolizumab (Entyvio®) · The Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland) · £47,898,609
- Combined Needles and Syringes Lot 1 · Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency · £15,264,000
source
Published on Contracts Finder. Contact details for named individuals are not reproduced on this site.